EAU 2013 - Programme Book - YouMed

Tuesday
10.00 - 10.20 Late breaking news I
318 Programme Book
Can Zometa prevent bone metastases in high risk prostate cancer patients? First Results of the Zometa
European Study (ZEUS).
M. Wirth, Dresden (DE)
Prostate cancer in China
Y-H. Sun, Shanghai (CN)
10.20 - 10.40 State-of-the-art lecture Is there a role for intermittent androgen deprivation?
T.L.J. Tammela, Tampere (FI)
10.40 - 11.20 Debate High risk PC: Surgery vs radiation vs systemic therapy
Moderator: M. Jewett, Toronto (CA)
Surgery: H. Van Poppel, Leuven (BE)
Radiation: A. Bossi, Villejuif (FR)
Systemic therapy: P. Iversen, Copenhagen (DK)
Aims and objectives
The optimal management for men presenting with high risk prostate cancer remains controversial.
Experts will debate the merits of radical prostatectomy, radiation therapy and systemic therapy alone or in
combination. At the end of the session, the delegates will better understand how to personalize the care of
the individual patient presenting with this life threatening disease to achieve the best chance of cure while
minimizing the burden of treatment.
11.20 - 11.35 Late breaking news II
Swedish Registry Study
P. Wiklund, Stockholm (SE)
11.35 - 12.15 Debate Why focal therapy instead of active surveillance for low risk prostate cancer
Moderator: F.C. Hamdy, Oxford (GB)
Pro: M. Emberton, London (GB)
Con: M. Wirth, Dresden (DE)
12.15 - 12.35 Report on the Consensus Statement for Prostate Cancer Prevention
J. Cuzick, London (GB)
12.35 - 13.05 Update European PSA screening
ERSPC perspective
J.E. Hugosson, Göteborg (SE)
Aims and objectives
Screening for prostate cancer is controversial. While a large randomized study has shown a benefit
of screening in terms of prostate cancer mortality. Generally accepted evidence on a proper balance on
advantages and disadvantages is lacking. The purpose of this session will be to inform on the present status
of screening and proper decision taking.